Reshape Lifesciences announced on Tuesday that its modified treatment for obesity has received approval from the Food and Drug Administration (FDA). The company is now preparing for the product launch of its modified Lap-Band 2.0 FLEX in the U.S. This development has fueled a 43% surge in shares, which are now valued at 36 cents after-hours.
Codorus Valley Bancorp to be Acquired by Orrstown Financial Services
Orrstown Financial Services, the parent company of Orrstown Bank, has agreed to acquire Codorus Valley Bancorp for $207 million in stock. The deal is expected to be finalized in the third quarter of 2024, resulting in the creation of a Pennsylvania and Maryland community bank with approximately $5.2 billion in assets. As a result of this news, shares have risen by 5.5% to reach $21.66 after-hours.
Caribou Biosciences Receives FDA Approval for Phase 3 Trial
Caribou Biosciences has received FDA approval for the trial design of its Phase 3 trial for CB-010, a promising treatment for large B cell lymphoma. The company plans to initiate this Phase 3 trial by the end of 2024. Consequently, there has been a 4.1% increase in shares, which are now valued at $5.88 after-hours.
